Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-02-17 Legal Proceedings Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled 'Press Release' and dated '17 February 2016'. It announces clinical trial progress ('Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial') and provides key operational updates, including recruitment status and upcoming data presentation. This structure—a brief announcement of recent operational or financial highlights, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general press release. Since it focuses on operational progress and clinical milestones rather than comprehensive financial statements (like 10-K or IR) or management discussion (like MDA), and it is not a transcript (CT) or a formal proxy/governance document, the most appropriate classification is Earnings Release (ER), as these often accompany or precede formal earnings reports to disseminate key news.
2016-02-17 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 2, 2016, announcing the extension of a collaboration between Bone Therapeutics and Kasios to develop integrated solutions for spinal fusion. It details the strategic partnership, the technology involved (ALLOB®, 3D printed cages), and includes quotes from the CEOs. This type of announcement, detailing a strategic business development or partnership, does not fit the specific categories like 10-K, ER, or IR. It is a general corporate announcement regarding business strategy and development. Since it is not a formal regulatory filing (like a 10-K or a specific transaction report) but rather a press release detailing a business agreement, the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'M&A Activity' (TAR) if the collaboration implied a merger, which it does not. Given the content is a strategic partnership announcement, and there is no specific category for 'Strategic Partnership Announcement', RNS serves as the best general corporate announcement fallback. However, upon reviewing the definitions, this is a standard press release announcing a business development. If the document were related to a takeover or merger, TAR would apply. Since it is a general corporate update/press release, RNS is the most suitable fallback for non-standard filings. Given the context of financial reporting databases, press releases announcing strategic collaborations often fall under general regulatory/corporate news feeds.
2016-02-02 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and dated '2 February 2016'. It announces a business development: the extension of a collaboration between Bone Therapeutics and Kasios regarding spinal fusion products. This type of announcement, detailing strategic business updates, partnerships, or operational milestones outside of mandatory financial reporting (like 10-K or ER), typically falls under general corporate news. Since it is not a formal financial report (10-K, IR, ER, MRQ), a management discussion (MDA), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV), the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for press releases that don't fit a more specific operational or financial code, or potentially 'LTR' if it were legal news, but here it is a commercial update. Given the options, RNS serves as the best fit for a general corporate press release announcing a strategic partnership extension.
2016-02-02 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 20, 2016, announcing that Bone Therapeutics reaffirms its eligibility for the PEA-PME (a French regulated investment scheme for SMEs). This type of announcement, which communicates a specific regulatory or financial status update outside of standard periodic reports (like 10-K or IR), fits best under general Regulatory Filings (RNS) or potentially Capital/Financing Update (CAP) if the tax benefit is considered a financing aspect. However, since it is a specific, non-periodic regulatory status confirmation, RNS is the most appropriate general regulatory category for such specific announcements that don't fit other defined categories like ER, DIV, or DIRS. It is not an Earnings Release (ER), a full report (10-K/IR), or a management change (MANG). Given the nature of confirming eligibility for a specific investment vehicle, RNS (Regulatory Filings) serves as the best fit among the provided options for a non-standard regulatory update.
2016-01-20 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' dated '18 January 2016'. It announces the initiation of a new Phase IIA clinical study for the product ALLOB®, detailing patient enrollment, study design, and management commentary. This format—a formal announcement of business or clinical progress via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it announces specific operational/clinical progress rather than just a dividend (DIV) or management change (MANG), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the context of clinical trial updates, which often accompany or substitute for quarterly updates, and the structure being a news announcement, ER is a strong candidate. However, since it is purely a clinical trial update and not explicitly tied to quarterly earnings figures, and it is a formal announcement, it could also be RNS. Comparing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is a clinical update, not a financial results highlight. Therefore, the most appropriate general category for a significant, non-standard operational announcement that isn't a specific report type is Regulatory Filings (RNS), as it serves as a general regulatory disclosure to the market. Given the high specificity of the other codes, and this being a press release announcing clinical progress, RNS is the safest fallback for a significant, non-financial-results announcement.
2016-01-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 18, 2016, announcing the extension of a clinical study (ALLOB®) for treating multiple fractures with delayed consolidation. It details the study design, patient recruitment, and quotes the CEO. This type of announcement, detailing operational and clinical development news, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a corporate announcement. Since it is not a formal regulatory filing like a 10-K, a specific financial report (IR, MRQ), or a transcript (CT), and it is a direct announcement of company activity/development, it fits best under the general category for corporate news releases that aren't strictly about dividends, management changes, or capital structure. However, given the context of financial reporting databases, press releases announcing clinical trial updates often fall under the general 'Regulatory Filings' (RNS) if they don't fit a more specific operational category like ER or CT. Since this is a detailed operational update rather than a brief regulatory notice, and it is not a formal financial report, I will check the definitions. It is not an ER (which focuses on financial results), nor is it a CT, MANG, or DIV. It is a significant corporate update. In many classification schemes, detailed operational press releases that aren't earnings summaries default to a general announcement category. RNS (Regulatory Filings) is the fallback for miscellaneous filings. Given the content is a detailed operational update about a clinical trial extension, and it lacks the structure of a formal financial report, RNS is the most appropriate general classification for non-standard corporate announcements.
2016-01-18 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.